title: Hypertensive patients from two rural Chinese counties respond differently to benazepril: the Anhui Hypertension Health Care Study.
abstract: OBJECTIVE
  Essential hypertension, as a complex disorder with unknown etiology cause, is a major public health problem worldwide. Patients need constant drug therapy to maintain their blood pressure in a normal range. However, the current facts suggest that the treatment is not optimized in a large number of patients, and as a result they are at risk for compliance resulting in uncontrolled blood pressure. Genetic and environmental factors associated with individual variation in response to anti-hypertensive drug remain largely unknown.
  
  
  METHODS
  In order to illustrate the existence and to attempt to identify the factors modifying drug effect, we conducted a large-scale follow-up study in two Chinese rural counties differing in both genetic background and residential environment. Hypertensive patients were treated with benazepril, a commonly used angiotensin converting enzyme inhibitor, for 15 days, and the end-point effect was evaluated.
  
  
  RESULTS
  We found that there were large and significant differences in drug response between subjects from two counties, even after adjustment for known factors. The responses to benazepril, measured in diastolic blood pressure drop, in male patients from Yuexi was twice as effective as their counterparts from Huoqiu.
  
  
  CONCLUSIONS
  These results suggest that adjustment of treatment regimen is necessary to improve efficacy, and it could be done at the population level to make it more feasible and affordable.
authors.affiliation: School of Life Science, University of Science and Technology in China, Hefei, China.
authors.forename: Dong
authors.initials: D
authors.lastname: Li
authors.forename: Houxun
authors.initials: H
authors.lastname: Xing
authors.forename: Ke
authors.initials: K
authors.lastname: Hao
authors.forename: Shaojie
authors.initials: S
authors.lastname: Peng
authors.forename: Di
authors.initials: D
authors.lastname: Wu
authors.forename: Wenwei
authors.initials: W
authors.lastname: Guang
authors.forename: Aiqun
authors.initials: A
authors.lastname: Huang
authors.forename: Yuanping
authors.initials: Y
authors.lastname: Wang
authors.forename: Yan
authors.initials: Y
authors.lastname: Zhang
authors.forename: Yunxian
authors.initials: Y
authors.lastname: Yu
authors.forename: Jianping
authors.initials: J
authors.lastname: Li
authors.forename: Changzhong
authors.initials: C
authors.lastname: Chen
authors.forename: Binyan
authors.initials: B
authors.lastname: Wang
authors.forename: Guoying
authors.initials: G
authors.lastname: Zhu
authors.forename: Yong
authors.initials: Y
authors.lastname: Huo
authors.forename: Dafang
authors.initials: D
authors.lastname: Chen
authors.forename: Alayne
authors.initials: A
authors.lastname: Ronnenberg
authors.forename: Tianhua
authors.initials: T
authors.lastname: Niu
authors.forename: Xiping
authors.initials: X
authors.lastname: Xu
mesh_terms: D000328:Adult; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001552:Benzazepines / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects*; D001823:Body Composition / Q000502:physiology; D002681:China / Q000453:epidemiology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000453:epidemiology; D007407:Interviews as Topic; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D017891:Pharmacoepidemiology; D012423:Rural Health / Q000706:statistics & numerical data*; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents; D001552:Benzazepines; C044946:benazepril